Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is associated with reduced delivery of DHA and eicosapentaenoic acid (EPA) to the brain before the onset of cognitive impairment. METHODS: 33 individuals were provided with a vitamin B complex (1 mg vitamin B12, 100 mg of vitamin B6 and 800 mcg of folic acid per day) and randomized to 2,152 mg of DHA per day or placebo over 6 months. 26 individuals completed both lumbar punctures and MRIs, and 29 completed cognitive assessments at baseline and 6 months. The primary outcome was the change in CSF DHA. Secondary outcomes included changes in CSF EPA levels, MRI hippocampal volume and entorhinal thickness; exploratory outcomes were measures of cognition. FINDINGS: A 28% increase in CSF DHA and 43% increase in CSF EPA were observed in the DHA treatment arm compared to placebo (mean difference for DHA (95% CI): 0.08 µg/mL (0.05, 0.10), p<0.0001; mean difference for EPA: 0.008 µg/mL (0.004, 0.011), p<0.0001). The increase in CSF EPA in non-APOE4 carriers after supplementation was three times greater than APOE4 carriers. The change in brain volumes and cognitive scores did not differ between groups. INTERPRETATION: Dementia prevention trials using omega-3 supplementation doses equal or lower to 1 g per day may have reduced brain effects, particularly in APOE4 carriers. TRIAL REGISTRATION: NCT02541929. FUNDING: HNY was supported by R01AG055770, R01AG054434, R01AG067063 from the National Institute of Aging and NIRG-15-361854 from the Alzheimer's Association, and MGH by the L. K. Whittier Foundation. This work was also supported by P50AG05142 (HCC) from the National Institutes of Health. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Omega-3 fatty acids EPA and DHA: Health benefits throughout life
Swanson, D., Block, R., & Mousa, S. A. (2012) · Advances in Nutrition · doi:10.3945/an.111.000893 · Cited by 1,575
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979 · cited 7×
“[41] Manson JE , Cook NR , Lee I-M , Christen W , Bassuk SS , Mora S , et al.”
BackgroundInfluentialHead (2012) · doi:10.1001/archneurol.2011.845 · Cited by 267
Soininen, H., Solomon, A., Visser, P. J., Hendrix, S. B., Blennow, K., Kivipelto, M., Hartmann, T., Hallikainen, I., Hallikainen, M., Helisalmi, S., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30332-0 · Cited by 241
Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers
Tao, Q., Ang, T. F. A., DeCarli, C., Auerbach, S. H., Devine, S., Stein, T. D., Zhang, X., Massaro, J., Au, R., & Qiu, W. Q. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3597 · Cited by 239 · cited 2×
“This finding contributes to our understanding as to why APOE 4 carriers with limited omega-3 intake might be at a greater risk of neuroinflammation and AD progression [30] .”
BackgroundRelationships between plasma fatty acid composition and coronary artery disease.
Itakura, H., Yokoyama, M., Matsuzaki, M., Saito, Y., Origasa, H., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Kita, T., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5876 · Cited by 218 · cited 2×
“[10] Itakura H , Yokoyama M , Matsuzaki M , Saito Y , Origasa H , Ishikawa Y , et al.”
Background
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“Preclinical and clinical studies of DHA supplementation have had success in rebalancing DHA levels and improving cognitive outcomes [266], although it seems to be ineffective in APOE4 carriers [267, 268].”
BackgroundImportance of EPA and DHA Blood Levels in Brain Structure and Function
von Schacky, C. (2021) · Nutrients · doi:10.3390/nu13041074 · Cited by 174
Gutierrez, L., Folch, A., Rojas, M., Cantero, J. L., Atienza, M., Folch, J., Camins, A., Ruiz, A., Papandreou, C., & Bulló, M. (2021) · Nutrients · doi:10.3390/nu13113728 · Cited by 105
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Ebright, B., Assante, I., Poblete, R. A., Wang, S., Duro, M. V., Bennett, D. A., Arvanitakis, Z., Louie, S. G., & Yassine, H. N. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01084-7 · Cited by 56
Self-citation
Metadata
- Authors
- Arellanes, I. C., Choe, N., Solomon, V., He, X., Kavin, B., Martinez, A. E., Kono, N., Buennagel, D. P., Hazra, N., Kim, G., D'Orazio, L. M., McCleary, C., Sagare, A., Zlokovic, B. V., Hodis, H. N., Mack, W. J., Chui, H. C., Harrington, M. G., Braskie, M. N., Schneider, L. S., & Yassine, H. N.
- Venue
- eBioMedicine
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 59
- Pages
- 102883
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W3042880599
- Cited by
- 134
- References
- 16
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1016/j.ebiom.2020.102883
- The paper
- Arellanes, I. C., Choe, N., Solomon, V., He, X., Kavin, B., Martinez, A. E., Kono, N., Buennagel, D. P., Hazra, N., Kim, G., D'Orazio, L. M., McCleary, C., Sagare, A., Zlokovic, B. V., Hodis, H. N., Mack, W. J., Chui, H. C., Harrington, M. G., Braskie, M. N., . . . Yassine, H. N. (2020). Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. eBioMedicine. https://doi.org/10.1016/j.ebiom.2020.102883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.